Bristol-Myers Squibb’s $74 billion Celgene takeover has been a roller coaster, with some Revlimid patent wins on the upside and, on the down, an FTC-forced sale of blockbuster Otezla. But the FDA just handed the merger partners another win. More: In a
read moreA group of investors sued Novo Nordisk in Denmark for allegedly misleading the public about its insulin franchise’s downward spiral. The lawsuit claims $1.75 billion in losses as pricing pressures and falling sales sent share prices downward—and as Novo points
read moreGlenmark Pharmaceuticals’ makeover is painfully loaded with slow revenue growth and high capital spend simultaneously. In the hope of reducing debt, the Indian drugmaker now plans to sell some of its noncore assets after spinning off its API and innovative
read moreTwo of Roche’s oncology blockbusters, Herceptin and Avastin, are facing dire straits as first-ever biosim competitors have entered the U.S. market. Now, a major insurer is putting its money on the new guys. Amgen’s new guys, to be exact. More:
read moreFor the indication of ROS1-positive, metastatic non-small cell lung cancer (NSCLC). More: Rozlytrek bags FDA approval Source: News
read moreUK Meds has announced a partnership with Onfido to make buying prescription-only medicines online much safer. More: £500,000 injected into ‘innovative’ AI online safety software Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals